BioAlliance Pharma files Loramyc in the US for candidiasis
This article was originally published in Scrip
BioAlliance Pharma SA has submitted an NDA to the US FDA for its antifungal Loramyc (miconazole Lauriad) mucoadhesive buccal tablets for the treatment of oropharyngeal candidiasis in immunocompromised patients.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.